Low lymphocyte count and high monocyte count predicts poor prognosis of gastric cancer

Feng, Fan; Zheng, Gaozan; Wang, Qiao; Liu, Shushang; Liu, Zhen; Xu, Guanghui; Wang, Fei; Guo, Man; Lian, Xiao; Zhang, Hongwei

doi:10.1186/s12876-018-0877-9

Cited by 107 publications

(97 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Tumour inflammatory microenvironments are complex and dynamic, involving crosstalk between various immune cells and tumour cells. Inflammatory prognostic scores such as the NLR, PLR, and LMR calculated using immune cellrelated values have shown promise in various tumour types [16][17][18][19]. In addition, the efficacy of the SIRI has been reported in limited types of cancer, such as liver [20], pancreatic [3], gastric [4], and nasopharyngeal [5] cancers.…”

Section: Discussionmentioning

confidence: 99%

Combining the Fibrinogen/Albumin Ratio and Systemic Inflammation Response Index Predicts Survival in Resectable Gastric Cancer

Zhang

Ding

Wang

et al. 2020

Gastroenterology Research and Practice

View full text Add to dashboard Cite

Aims. Predicting the prognosis of gastric cancer using tumour-node-metastasis (TNM) staging is difficult as patients with the same TNM stage exhibit different prognoses. Methods. This study investigated the prognostic value of the preoperative fibrinogen/albumin ratio (FAR)-systemic inflammation response index (SIRI) score in resectable gastric cancer (rGC). Results. Clinicopathological features of 231 rGC patients were analysed retrospectively. Patients were divided into three groups: FAR-SIRI score 2 (FAR≥0.071 and SIRI≥0.84), 1 (FAR<0.071 and SIRI≥0.84), and 0 (SIRI<0.84). Higher FAR-SIRI scores were associated with larger tumours, poorer differentiation, and advanced TNM stage (P<0.05). Compared to those with FAR-SIRI scores of 0, patients with scores of 2 had poorer overall survival (OS). The FAR-SIRI score was an independent prognostic factor for OS in rGC. Conclusion. The present data demonstrated that FAR-SIRI scores predicted radical gastric cancer surgical outcomes and may serve as a blood marker for identifying high-risk patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Combining the Fibrinogen/Albumin Ratio and Systemic Inflammation Response Index Predicts Survival in Resectable Gastric Cancer

Zhang

Ding

Wang

et al. 2020

Gastroenterology Research and Practice

View full text Add to dashboard Cite

show abstract

“…Lymphocytes play a prominent role in tumor-related immunology and lymphopenia has been reported to be associated with poor prognosis in many solid tumors including NSCLC, melanoma, gastric-, breast-, and colon cancers. 12,35,36 Cho et al investigated the effects of lymphopenia on OS and progression-free survival (PFS) in immunotherapy treated patients and found that lymphopenia within 0-2 months from the initiation of immunotherapy also showed significantly inferior OS and PFS. 12 Accordingly, changes in ALC should be carefully evaluated in patients who are future candidates for immunotherapy.…”

Section: Discussionmentioning

confidence: 99%

Longitudinal analysis of complete blood count parameters in advanced‐stage lung cancer patients

et al. 2020

View full text Add to dashboard Cite

Background Metastatic lung cancer is a debilitating disease, but with the advances in immunotherapy, therapeutic options have vastly increased. Numerous complete blood count parameters (CBC) have been described as easily accessible biomarkers that might predict response to immunotherapy. However, to date, no comprehensive study has been performed on the longitudinal changes of these parameters during cancer progression. Methods The clinicopathological variables and CBC parameters of 986 advanced stage lung cancer patients were retrospectively analyzed. Blood tests were performed as part of the routine checkup and the results were recorded at the time of the diagnosis of the primary tumor, the diagnosis of brain or bone metastases, and also during the last available follow‐up. Results In the experimental subcohort, 352 and 466 patients were diagnosed with brain and bone metastases, respectively. The control group consisted of 168 patients without clinically detectable or other distant organ metastases. In our longitudinal analyses, we found significantly decreasing absolute lymphocyte count (ALC: P < 0.001), and significantly increasing absolute neutrophil count (ANC: P < 0.001) levels in all patient subgroups, irrespective of histopathological type and metastatic site. Interestingly, patients with brain metastases had significantly descending‐ascending platelet count (PLT) trendlines ( P < 0.001), while the bone metastatic subgroup exhibited significantly ascending‐descending trendlines ( P = 0.043). Conclusions Significantly decreasing ALC, significantly increasing ANC and fluctuating PLT levels may be found in brain and bone metastatic lung cancer patients during disease progression. Our findings might contribute to improve personalized healthcare in this devastating malignancy. Key points Significant findings of the study Significantly decreasing ALC, and significantly increasing ANC levels can be found in advanced‐stage lung cancer patients during disease progression Patients with brain metastases have descending‐ascending PLT trendlines, while patients with bone metastases exhibit ascending‐descending trendlines during disease progression What this study adds The descending values for ALC, and the ascending mean values for PLT and ANC, might be suggestive of poor response to second‐ or third‐line immunotherapy in advanced‐stage lung cancer patients. The current study might help to improve patient selection and treatment strategies for brain and/or bone metastatic lung cancer patients.

show abstract

“…Generally, high numbers/percentages of circulating monocytes indicate poor clinical prognosis in cancer 13 , suggesting that the level of monocytes in blood may in uence tumor development. In line with this hypothesis, it was recently shown that the peripheral count of monocytes was associated with the density of tumor-associated macrophages in colorectal cancer 14,15 . During in ammation, metabolic and epigenetic rewiring has been identi ed as important mechanisms of monocyte, and more generally myeloid cell, production and function 16 .…”

Section: Introductionmentioning

confidence: 60%

Pro-atherogenic diet accelerates tumor growth in mice through IL-1β and myeloid cell-derived VEGF-A

Tran¹,

Esposito²,

Montabord³

et al. 2020

Preprint

View full text Add to dashboard Cite

Aims: Myeloid inflammatory cells are recruited to the tumor microenvironment and subsequently educated in situ to acquire a pro-invasive, pro-angiogenic and immunosuppressive phenotype. Components of the metabolic syndrome are known to aggravate tumorigenesis in part through myeloid cell activation. We hypothesized that consumption of a high fat/high cholesterol pro-atherogenic diet and its associated low-grade inflammation would accelerate the initiation of solid tumors. Methods and results: Here, we show that two-week feeding of wildtype C57BL/6J mice with a pro-atherogenic diet increases the pool of circulating inflammatory Ly-6Chi monocytes available for initial melanoma development and amplifies the accumulation of myeloid cells within the tumor microenvironment, in an IL-1β-dependent manner. Under pro-atherogenic diet feeding, myeloid cells display heightened pro-angiogenic, pro-inflammatory and immunosuppressive activities. Within the first days after tumor implantation, myeloid cells become the main producer of VEGF-A in the tumor. Depletion of Ly-6Chi monocytes in mice fed with a pro-atherogenic diet limits immune cell infiltration in the tumor, and inhibits tumor growth. IL-1β deficiency or specific inhibition of VEGF-A in myeloid cells recapitulates the beneficial effect of Ly-6Chi monocyte depletion, suggesting their complementary roles in tumorigenesis in the context of mild hyperlipidemia. Conclusion: Our study shows that dyslipidemia provide high amounts of activated myeloid cells with pro-tumoral activity and shed light on cross-disease communication between cardiovascular pathologies and cancer. Translational Perspective: In this study we demonstrate that dyslipidemia accelerates the development of solid tumors through the increased infiltration of Ly6Chi monocytes that differentiate into pro-tumoral myeloid cells. These findings demonstrate that dyslipidemia can silently boost tumor development in normal-weight individuals through the action of IL-1β and VEGF-A. Our work sheds light on the potential benefit of targeting IL-1β and VEGF-A in cancer patients with moderate dyslipidemia.

show abstract

Low lymphocyte count and high monocyte count predicts poor prognosis of gastric cancer

Cited by 107 publications

References 34 publications

Combining the Fibrinogen/Albumin Ratio and Systemic Inflammation Response Index Predicts Survival in Resectable Gastric Cancer

Combining the Fibrinogen/Albumin Ratio and Systemic Inflammation Response Index Predicts Survival in Resectable Gastric Cancer

Longitudinal analysis of complete blood count parameters in advanced‐stage lung cancer patients

Pro-atherogenic diet accelerates tumor growth in mice through IL-1β and myeloid cell-derived VEGF-A

Contact Info

Product

Resources

About